Pfizer's revelation this week that it plans to slice jobs in Puerto
Rico is the latest in a string of blows for this popular offshore
manufacturing location.
The US Food and Drug Administration (FDA) has given stakeholders an
extra month to get their views in on scrapping epinephrine inhalers
containing CFCs.
Pfizer yesterday announced a multi-million dollar pay-off to
ex-partner Nektar Therapeutics, but the details of the deal reveal
not only Nektar's concerns for its future, but also that Pfizer is
still keeping its fingers in the...
As of next year Chinese pharmaceutical manufacturers will face a
tougher time gaining good manufacturing practice (GMP)
certification after the country's regulator signalled new and
stricter standards were on the way.
NPIL Pharma last week told workers at its former Pfizer plant in
Morpeth, UK that the company is considering hiving off jobs in a
bid to maintain the site's viability.
A new Belgian company has joined the throng of pharmas tapping into
the booming drug delivery business, but claims that its unique
technologies will carve it a place as one of the industry's key
players.
A new report highlights a number of worrying trends emerging in
regard to the increasing number of fake pharmaceuticals
infiltrating supply chains around the globe.
There are lessons to be learned about the importance of rigorous due diligence of pharma contractors, now that Inyx' customers are facing possible supply issues and a scramble to find alternative manufacturers after the firm's collapse.
Swiss pharma Novartis today announced the largest manufacturing investment in its history, revealing plans for a $700m (€486.5m) biotech facility to be built alongside its new solid dose plant in the low cost, high quality biopharma hub of Singapore.
GlaxoSmithKline (GSK) is planning to strip itself down closer to
the bare bones of the business through further outsourcing and
offshoring, with hopes of making itself into a lean, mean, pharma
machine.
Sigma-Aldrich continued its strong year with both revenues and
pre-tax profits showing strong double-digit growth in the third
quarter predicting it will break the $2bn (€1.4bn) revenue mark
this year.
Pfizer revealed today that it is abandoning its once-touted
blockbuster Exubera, ending months of speculation as to whether the
fledging world-first inhalable insulin would sink or swim in the
fierce waters of pharma.
SAFC has announced its plans to build a new high potency
conjugation suite at its Missouri manufacturing plant in order to
target pharma clients developing novel anti-cancer drug conjugates.
UK-based Bespak, one of the two contract manufacturers of Pfizer's
inhaled insulin Exubera, confirmed on Friday it has been approached
by a potential buyer.
Catalent Pharma Solutions, the firm born from the spin out of
Cardinal Health's contract manufacturing business, is reorganising
its production facilities with an expansion of its UK site and the
divestiture of some of its French...
Wyeth has signed a license agreement with French firm Flamel
Technologies to apply the company's second innovative drug delivery
technology to one of its protein therapeutics.
Britain's Eden Biodesign has been selected by Cancer Research UK as
the beneficiary of two new biomanufacturing contracts as its
biomanufacturing business continues to grow.
Acambis has had its smallpox vaccine approved by the US, coming one
step closer to closing another supply contract for the US Strategic
National Stockpile.
Reformulations of pseudoephedrine- and ephedrine-containing drugs
in the UK look unlikely following the announcement of less extreme
restrictions on the sale of the pharmaceuticals.
In the latest phase of growth at chemical firm SAFC's flagship high
potency active pharmaceutical ingredients (HPAPIs) facility in
Madison, Wisconsin, the site will be treated to another
multi-million dollar expansion and new...
Lonza's $200m (€147m) investment in China is continuing to shape up
as the firm announced its new small-scale exclusive synthesis
manufacturing plant will be up and running next month.
ALK-Abello will be funding a new DKK 300m (€40.3m) production line
dedicated to its oral grass pollen allergy vaccine at Catalent
Pharma Solutions' UK facility.
GlaxoSmithKline (GSK) and Merck Sharp & Dohme (MSD) have made
further moves in their plans to boost their presence in Singapore,
a region growing in popularity for biopharmaceutical research and
manufacture.
China has announced an initial $1.7bn investment to bolster its
currently questionable ability to effectively monitor the quality
of the food and drugs manufactured within its borders.
A US bankruptcy court judge ruled on Friday that Puerto Rican-based
pharma services firm Inyx USA be put under the control of an
independently-appointed trustee.
German pharma firm Stada has acquired Russian pharmaceuticals group
Makiz in a deal worth up to €135m, giving the company a sturdy
foothold in the growing Russian market and enhanced in-house
production capacity.
The latest twists and turns in the Inyx Inc. bankruptcy saga
include an attempted power seize by its creditor, fraud allegations
thrown around courtrooms and in the media, the resignation of Inyx'
accountants, and increasing...
Abraxis BioScience has snapped up another manufacturing plant in
its drive to expand production capabilities, this time announcing
the purchase of Watson Pharmaceuticals' sterile injectables plant.
Indian biotech heavyweight Biocon has today announced that its
joint venture with Abu Dhabi-based Neopharma has spawned new
company NeoBiocon, operating out of one of Dubai's newest
biotechnology parks.
A novel spring-powered inhaler system to deliver the blockbuster
COPD (chronic obstructive pulmonary disease) treatment Spiriva
(tiotropium) has successfully completed the EU approval process,
paving the way for its introduction into...
Lab equipment specialist Sotax has announced the creation of a new contract research organisation (CRO) focused exclusively on dissolution testing services.
The US Food and Drug Administration (FDA) has released a draft
guideline document outlining a model for implementing the
International Conference on Harmonization's (ICH) Q10.
US biopharmaceutical company VGX has strengthened its position in
the plasmid DNA area with the award of two new patents covering the
use and manufacture of plasmid DNA.
As Outsourcing-Pharma.com continues to investigate the
circumstances of the Inyx group's insolvency problems, it can
be revealed that some of the senior management have been
involved at a senior level in other firms that have...
Indian pharmaceutical manufacturing company Shasun Chemicals and
Drugs has now got its eye fully on the US market after recent
approval of its new formulation facility in Puducherry.
British contract manufacturing organisation (CMO) NextPharma
Technologies has announced a €30m fundraising round and the
acquisition of Bioserv, another CMO based in the US.
AstraZeneca has sold a manufacturing plant in France to a contract
manufacturer who will continue to supply the drug giant with its
products under a new outsourcing contract.
Bespak, one of the two contract manufacturers of Pfizer's inhaled
insulin Exubera, has announced it will cut a "significant" number
of jobs as sales of the once-touted blockbuster are falling short
of expectations.
Microtest Laboratories and Texcel Medical have teamed up to offer
biopharma firms services to help them overcome the hurdles of
developing "combination products" - a fast-growing market.
Patheon is teaming up with formulation development services firm
Senopsys to offer pharma companies combined services to test and
improve drug flavour.
US firm Aptuit has announced it will invest $100m (€75m) in
India-based Laurus Labs to form a new joint venture - just a few
months after splurging a similar amount to expand its capabilities.
Dutch ingredients firm DSM has announced plans to carve out its
anti-infectives business and boost its presence in Asian markets
following a review of the active ingredient unit.
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...
